Product logins

Find logins to all Clarivate products below.


Osteoarthritic Pain | Treatment Algorithms | Claims Data Analysis | US | 2024

In the United States, osteoarthritic pain affects about 32 million people; an aging population and the increasing prevalence of obesity are predicted to fuel additional growth. Several treatment classes may be prescribed to reduce the pain and/or increase patients’ mobility, such as intra-articular agents, antidepressants, NSAIDs, and antiepileptic drugs (AEDs). However, widely applicable and well-tolerated alternatives are needed. In this crowded and largely generic market, a detailed understanding of treatment patterns is essential for the successful introduction of a novel analgesic.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed osteoarthritic pain? What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoarthritic pain patients?
  • How has Pacira’s Zilretta been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of osteoarthritic pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of osteoarthritic pain patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Pacira Biosciences, Collegium Pharmaceuticals, Protega Pharmaceuticals, Averitas Pharma, Kowa

Key drugs: Zilretta, injectable corticosteroids, hyaluronic acid preparations, NSAIDs, antidepressants, AEDs (e.g., gabapentin), opioids (e.g., Xtampza ER), Qutenza

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in…
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…